Krka Settles Out of Court over Donepezil Marketing in Norway

Ljubljana, 24 February - Drug maker Krka and its subsidiary Krka Sverige AB reached on Wednesday an out-of-court settlement with Eisai Co., Ltd. and Pfizer AS, the parent company said in a press release. Krka will receive EUR 1.55m and will continue to market its Donepezil Krka, used to treat Alzheimers disease, in Norway.